权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Ack1: A Critical Regulator of Hormone-Refractory Prostate Cancer

Ack1：激素难治性前列腺癌的关键调节因子

基本信息

批准号：
8657844
负责人：
Nupam P Mahajan
金额：
$ 31.41万
依托单位：
H. LEE MOFFITT CANCER CTR & RES INST
依托单位国家：
美国
项目类别：
财政年份：
2010
资助国家：
美国
起止时间：
2010-06-08 至 2016-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8657844
关键词：
Ablation Adenocarcinoma Affect Agar Age American Amino Acids Anchorage-Independent Growth Androgen Antagonists Androgen Receptor Androgens Antibodies Applications Grants Bicalutamide Binding Biological Biological Assay Cancer Etiology Cancer Patient Castration Cells Cessation of life ChIP-on-chip Data Development Disease EGF gene Enhancers Event Flutamide Gene Expression Gene Targeting Genes Genetic Transcription Growth Hormones Implant LAPC4 LNCaP Ligands Malignant - descriptor Malignant neoplasm of prostate Mediating Molecular Monitor Mus NKX3-1 gene Neoplasms Nude Mice Patients Phosphorylation Phosphotransferases Play Premalignant Prostate Prostatic Intraepithelial Neoplasias Protein Tyrosine Kinase Pyrimidine Receptor Activation Receptor Protein-Tyrosine Kinases Receptor Signaling Refractory Research Proposals Reverse Transcriptase Polymerase Chain Reaction Role Staging Staining method Stains TMPRSS2 gene Testing Therapeutic Tissue Microarray Transactivation Transcriptional Activation Transgenic Mice Tyrosine Tyrosine Phosphorylation Xenograft procedure androgen independent prostate cancer castration resistant prostate cancer cell growth deprivation hormone refractory prostate cancer inhibitor/antagonist men mouse model pre-clinical probasin promoter receptor expression small molecule tumor growth tumor xenograft

项目摘要

ABSTRACT Androgen receptor (AR) plays a critical role in progression of prostate cancer. We have recently demonstrated that Ack1 (also known as TNK2) regulates AR Tyr267-phosphorylation within the transactivation domain. While AR transcriptional activation by multiple tyrosine kinases is emerging as an alternate mode of AR activation, the precise role of Ack1 mediated AR Tyr267- phosphorylation in AR recruitment to the androgen responsive enhancers (ARE) and androgen- independent AR-responsive gene transcription is not fully understood. In this grant proposal we demonstrate that activated Ack1(pTyr284-Ack1) expression is upregulated as prostate cancer progresses and this activation is inversely correlated with the survival of prostate cancer patients. Since Ack1 regulates androgen-independent AR activity by its phosphorylation at Tyr267, we generated antibodies that specifically recognize pTyr267-AR. Neither pTyr267-AR expression nor its transcriptional activation was affected by anti-androgens e.g. bicalutamide/casodex and flutamide. However, a small molecule inhibitor of Ack1, 4-Amino-5,6- biaryl-furo[2,3-d]pyrimidine (YL3-026) not only inhibited Ack1 activation, but was able to suppress pTyr267-AR phosphorylation, binding to PSA, NKX3.1 and TMPRS2 promoters and inhibit AR transcription activity as seen by significant decrease in PSA gene expression. Our evidence indicates that targeting Ack1 kinase in prostate cancer patients could therefore be highly effective therapeutic strategy. In this proposal we will determine how AR Tyr267- phosphorylation regulates Androgen-Independent growth. Further, we will examine the ability of Ack1 inhibitor, YL3-026, to suppress androgen-independent transcription and xenograft tumor formation. Moreover, we will assess the ability of Ack1 inhibitor YL3-026 to suppress AR Tyr267-phosphorylation and prostatic intraepithelial neoplasia (PINs) formation in Prob-Ack1 transgenic mice.

摘要雄激素受体（AR）在前列腺癌的进展中发挥着关键作用。我们最近表明Ack 1（也称为TNK 2）调节AR Tyr 267-磷酸化，反式激活结构域虽然多种酪氨酸激酶的AR转录激活是 Ack 1介导的AR Tyr 267 - 267的确切作用作为AR激活的一种替代模式出现，在AR募集到雄激素应答增强子（ARE）和雄激素- 独立AR应答基因转录尚未完全理解。在这份赠款提案中，我们证实激活的Ack 1（pTyr 284-Ack 1）表达在前列腺癌中上调，并且这种激活与前列腺癌的存活率呈负相关患者由于Ack 1通过其磷酸化调节雄激素非依赖性AR活性， Tyr 267，我们产生了特异性识别pTyr 267-AR的抗体。pTyr267-AR 表达或其转录激活均受抗雄激素，比卡鲁胺/casodex和氟西汀。然而，Ack 1，4-氨基-5，6- 联芳基-呋喃并[2，3-d]嘧啶（YL 3 -026）不仅抑制Ack 1活化，而且能够抑制pTyr 267-AR磷酸化，与PSA、NKX3.1和TMPRS 2启动子结合，抑制AR转录活性，如PSA基因表达显著降低所示。我们因此，有证据表明，在前列腺癌患者中靶向Ack 1激酶可能是非常有效的治疗策略。在本提案中，我们将确定AR Tyr 267- 磷酸化调节雄激素非依赖性生长。此外，我们还将研究 Ack 1抑制剂YL 3 -026抑制雄激素非依赖性转录和异种移植肿瘤阵此外，我们将评估Ack 1抑制剂YL 3 -026抑制AR的能力， Prob-Ack 1中Tyr 267磷酸化和前列腺上皮内瘤变（PIN）形成转基因小鼠